A long-established and proven track record
The origins of the Acino – which was named “Schweizerhall” until 2008 – date back to 1836 when the company was founded around a saltworks operation near Basle. Subsequently, the company widened its activities to become both a manufacturer and trader and enlarged its portfolio with value added products including chemical specialties such as feeding stuffs, fertilizers and active pharmaceutical ingredients.
In 1994, the company went public on the Swiss stock exchange (SIX: ACIN) and gradually streamlined its business to focus on chemicals, pharmaceuticals and biotechnology. The subsequent years saw a focusing of the company’s activities on advanced drug delivery with the acquisition of Cimex Pharma AG, a Swiss supplier of complex solid oral dosage forms, in 2004, and of Novosis AG, Europe’s second largest manufacturer of transdermal patches and of biodegradable implants, in 2006.
The Biovac institute started
Change of the group and subsidiaries name to Acino
Biovac Holdings sold 40% stake to Litha Investment Group
Acquisition of combined Middle East and African Business of Cephalon Acquisition of Mepha’s production and R&D facilities and the business in MEA, LATAM and Asia. Commercialization of products under the brand “Acino Switzerland”
Biovac Consortium awarded contract with SA goverment in forming a PPP The Biovac Institute
Takeover by Avista Capital and Nordic Capital – Acino is delisted from the stock exchange
Litha Investments purchase extra 11% of Biovac Holdings
Name Changes to Litha Healthcare Holdings (LHH)
Acquisition of Copharm in Russia
Completed funding and planning for Biovac vaccine manufacturing site CT
Acquisition of PharmaStart in Ukraine
Litha Healthcare Group Lists on JSE
Move of the Headquarters to Zurich and start of a substantial re-organization in Switzerland
In–licensing agreement for the combination painkiller Maxigesic of AFT
Acquisition of MENA operations and product rights of Norgine B.V.
Aquisition of Takeda’s manufacturing plant in Põlva, Estonia
International NDB signed with Cpoint Capital Inc.
Biovac extends FSA with DOH to 2016
LHG acquires Goldex Healthcare and OTC Pharma SA
LHG purchases 100% of Pharmaplan for R590 m and merges business with Litha Pharma Division
Paladin Labs Inc. acquires 44.5% of LHG
Endo International plc, offers to 100% of majority shareholder Paladin Labs Inc.
Endo International plc, completes acquisition pf Paladin Labs Inc. effectively owing 65% of Litha Healthcare Group Limited
Endo and LHG announce intent to acquire balance of Litha shares
Endo International plc, completes 100% acquisition of Litha Healthcare Group Limited. Litha delists from JSE
Litha Healthcare Group changes to (Pty) Ltd.
Litha announces divestment of medical and vaccine business
Endo completes acquisition of Aspen product portfolio
The story continues